Sex disparities in case fatality rate after aneurysmal subarachnoid haemorrhage: a prospective longitudinal population-based cohort study Authors: Helena Janssen, Gabriel J E Rinkel, Jos P Kanning, Ynte M Ruigrok, Joanna D Schaafsma Published: 2026 ABSTRACT AbstractIntroductionWhile increased female susceptibility to intracranial aneurysm development and rupture is well-known, data on sex differences in case fatality rates (CFR) after aneurysmal subarachnoid haemorrhage (aSAH) remain conflicting. We aimed to investigate sex differences in 90-day CFR post-aSAH and identify explanatory factors.Patients and methodsThe UK Biobank is a prospective population-based cohort study, including 502,411 participants, with baseline assessments between 2006 and 2010. Participants who developed aSAH during follow-up were identified through linkage with hospitalisation records and national death registries. Primary outcome was 90-day CFR post-aSAH. Kaplan–Meier survival analysis and multivariable Cox proportional hazard regression assessed sex disparities in CFR and potential explanatory factors.ResultsWe included 990 participants with aSAH, 634 (64.0%) females (age 66.0 ± 8.4) and 356 males (36.0%) (65.1 ± 8.6). At 90 days, 214 of 634 females (33.8%) and 98 of 356 males (27.5%) had died (OR 1.34; 95% CI, 1.01–1.78). Survival analysis demonstrated a sex difference in 90-day CFR (log-rank P = .046) with early divergence and consistently lower survival probability in females. After adjusting for age and covariates that varied by sex at baseline and at time of aSAH, hazard ratio (HR) for case fatality in females was 1.15 (95% CI, 0.90–1.49). In sex-specific multivariable models, HRs for case fatality for age were 1.04 (95% CI, 1.02–1.06) in females and 1.04 (95% CI, 1.01–1.07) in males; for anti-hypertensives use 1.76 (95% CI, 1.23–2.51) and 1.98 (95% CI, 1.23–3.17); and for current smoking 1.87 (95% CI, 1.31–2.67) and 1.64 (95% CI, 0.95–2.82).Discussion and ConclusionFemales had a higher unadjusted 90-day CFR post-aSAH. This sex difference is partially explained by higher age at aSAH and differences in modifiable baseline risk factors such as hypertension and smoking. Introduction Subarachnoid haemorrhage due to a ruptured intracranial aneurysm (aSAH) is a devastating condition with high morbidity and case fatality and one of the few cardiovascular diseases that disproportionally affects females.1,2 While increased female susceptibility to aneurysm development and rupture are well-known, available data on sex differences in case fatality rates (CFR) following aSAH are conflicting. This could be due to heterogeneity in study designs, patient populations and the multifactorial nature of outcomes after aSAH. There is a need for high-quality studies on sex-specific CFR providing a sufficient sample size, appropriate confounder control, adequate SAH identification and inclusion of outside-hospital sudden deaths due to aSAH.3 Population-based studies can provide the extensive data required to address and bridge this important knowledge gap, since sex differences in CFR and the explanation thereof may lead to sex-specific management strategies. In this population-based study with data on risk factors, we studied sex differences in CFR after aSAH and aimed to identify factors explaining a potential sex disparity in CFR. Methods The design and results of this study are reported according to the Strengthening the Reporting of Observational Studies in Epidemiology statement.4 Study design and setting UK Biobank is a prospective, longitudinal population-based cohort study with extensive phenotypic and genotypic information from 502,411 participants, aged 40–70 years old, included at recruitment centres in England, Scotland and Wales (ukbiobank.ac.uk). Baseline data on self-reported health and clinical measurements were collected between 2006 and 2010 during nurse-led baseline assessment interviews and subsequently linked to the national hospitalisation and national death registries (National Health Service for England and Wales and National Health Service Central Register for Scotland) by UK Biobank data analysts. This enables long-term follow-up of participants and comprehensive capture of their health outcomes, including both hospital-admitted cases and deaths occurring outside the hospital setting. Dates and causes of death are contained within official death certificates. This study is based on the most recent censoring of 23 March 2021. Full details of the study methods have been published elsewhere.5 All UK Biobank participants provided informed consent, and the study was approved by the Northwest Multi-Centre Research Ethics Committee. Participants All adult participants with a first aSAH diagnosis after baseline assessment were identified using International Classification of Diseases (ICD) codes (ICD-9 430 and ICD-10 I60.0–I60.9) and included in the analysis. Follow-up for all participants started at inclusion in the UK Biobank and ended on the date of death or on 23 March 2021, whichever came first. Assessment of sociodemographic, lifestyle and clinical data From the UK biobank cohort, data on a wide range of demographic and lifestyle factors were systematically collected at the time of recruitment, including information on sex, ethnicity and socioeconomic status. Sex was defined according to the biological definitions of male and female. Ethnicity was self-reported by participants using UK Biobank-predefined categories: Asian or British Asian, Black or British Black, Chinese, Mixed, White or Other ethnic groups. Socioeconomic status was assessed by the Townsend Deprivation Index (positive values indicate areas with high material deprivation, negative values indicate relative affluence). Average household income before tax was self-reported (categorised as < 18,000, 18,000–30,999, 31,000–51,999, 52,000–100,000 and >100,000£). Smoking status and any alcohol use were self-reported as never, previous or current. Body mass index was documented in kg/m2. Data on self-reported medical conditions and associated use of the following chronic medications were registered: antidiabetics, anti-hypertensives, cholesterol medication and use of hormonal therapy. All aforementioned variables were assessed at the point of recruitment. The following data on aSAH and hospital admission were collected from hospitalisation records subsequent to UK Biobank recruitment: age at time of aSAH, aSAH ICD code, duration of hospital stay and discharge destination. Age was categorised into decades. ICD codes were defined in ICD-9 and ICD-10 and categorised as follows: SAH from an aneurysm in the anterior circulation (including ICD I60.0, I60.1 and I60.2), posterior circulation (including ICD I60.3, I60.4 and I60.5), unspecified/other SAH from intracranial artery (ICD I60.6 and I60.7) and unspecified/other SAH (ICD 430, ICD I60.8 and I60.9). Discharge destination was defined as home, other health care facility (hospital or rehabilitation facility), nursing or group home, missing or not applicable (deceased or not applicable with reason not specified). Dates of recruitment in UK Biobank, occurrence of aSAH, discharge, and, if applicable, the date of death were collected. Data collected at UK Biobank recruitment are referred to throughout as “baseline”, while data pertaining to the aSAH event are referred to as “at time of aSAH”. The interval duration between aSAH and discharge and aSAH and death was calculated. Time between aSAH and death was categorised into the following time periods: 30 days, 90 days, 1 year and beyond 1 year. Outcomes The primary outcome was CFR at 90 days post-aSAH. Secondary outcomes were CFR at different time points: at 30 days, at 1 year, overall CFR (from aSAH onset to study end date 23 March 2021). We assessed the presence of a potential sex disparity in CFR and evaluated factors influencing sex-specific case fatality. Statistical analysis We used descriptive statistics to assess and summarise baseline characteristics. These were presented as frequencies with percentages for categorical variables and as mean ± SD or median with IQR for continuous variables. Baseline characteristics were compared between sexes using Pearson Chi-square test for categorical variables and either an independent-sample T-test for normally distributed continuous variables or Mann–Whitney U test for non-normally distributed continuous variables. The CFRs were compared between males and females using odds ratios (OR) with their 95% CI. Survival analysis with Kaplan–Meier curve was used to visualise 90-day survival following aSAH stratified by sex, and the log-rank test was applied to assess for sex differences in survival curves. For all survival analyses, the time origin was defined as the date of aSAH. Multivariable Cox proportional hazard regression analysis was used to investigate the independent association between sex and 90-day case fatality, when adjusting for covariates, and sex-stratified Cox proportional hazard models were used to assess sex-specific predictors of 90-day case fatality. Covariates were selected based on established clinical and epidemiological evidence as known determinants of CFR after aSAH, retaining those covariates that differed significantly between sexes at baseline or at time of aSAH in the multivariable models. The following covariates were included in the multivariable model: age, alcohol status, smoking status, diabetes status, BMI, anti-hypertensive use, cholesterol-lowering medication and average household income. The influence of ICD code category was addressed through a sensitivity analysis presented in Supplementary material (Supplementary Material 1). Cox proportional hazard models estimated hazard ratios (HR) for case fatality with corresponding 95% CI. HR > 1 indicates a higher risk of death and HR < 1 indicates a lower risk of death. All participants were included in survival analyses. Missing data for covariates are reported as not available in Tables 1 and 2. Complete-case analysis was used for all multivariable Cox regression models. Statistical significance was considered as a P-value <.05. Table 1Patient characteristics at baseline study entry.General characteristicTotal (n = 990)Female, n (%) n = 634 (64.0%)Male, n (%) n = 356 (36.0%) P-value Smoking Never Current Previous Not available 316 (49.8)127 (20.0)186 (29.3)5 (0.8) 142 (39.9)63 (17.7)149 (41.9)2 (0.6) <.001 Alcohol Never Current Previous Not available 57 (9.0)548 (86.4)28 (4.2)1 (0.2) 13 (3.7)329 (92.4)13 (3.7)1 (0.3) .005 Diabetes Yes No Not available 25 (7.0)328 (92.1)3 (0.8) 20 (3.2)614 (96.8)0 .005 Drugs Cholesterol lowering agents Anti-hypertensive agents Anti-hyperglycaemic agents Hormonal agents Not available 102 (16.1)132 (20.8)3 (0.5)65 (10.3)5 (0.8) 83 (23.3)98 (27.5)5 (1.4)04 (1.1) .005 .016 .116.594 BMI (Mean)26.6 (SD 4.8)27.7 (SD 4.7) <.001 Townsend deprivation index −1.10 (SD 3.0)−1.11 (SD 3.4).951 Average household income (£) Not available <18,000 18,000 to 30,999 31,000 to 51,999 52,000 to 100,000 > 100,000 129 (20.4)164 (25.9)146 (23.0)105 (16.6)75 (11.8)15 (2.4) 39 (11)74 (20.8)77 (21.6)90 (25.3)64 (18.0)12 (3.4) <.001 Ethnicity Not available White Black Mixed Asian Chinese Other 3 (0.5)608 (95.9)8 (1.3)4 (0.6)6 (0.9)1 (0.2)4 (0.6) 3 (0.9)339 (95.2)6 (1.7)05 (1.4)03 (0.9).673Bold value: meets threshold for statistical significance P-value <0.05. Patient characteristics at baseline study entry. Bold value: meets threshold for statistical significance P-value <0.05. Table 2Patient characteristics at time of aSAH.Clinical informationTotal (n = 990)Female, n (%)Male, n (%) P-value Sex 634 (64.0)356 (36.0) <.001 Age at SAH Age category 40–49 50–59 60–69 70–79 80–8966.0 (SD 8.4)23 (3.6)118 (18.6)237 (37.4)243 (38.3)13 (2.1)65.1 (SD 8.6)16 (4.5)84 (23.3)137 (38.5)111 (31.2)9 (2.5).107.166 Decade aSAH 2000 2010 2020 34 (5.4)518 (81.7)82 (12.9) 28 (7.9)279 (78.4)49 (13.8).258 ICD-codes SAH Anterior circulation aneurysm Posterior circulation aneurysm Unspecified intracranial artery Unspecified/other SAH Not available 151 (23.8)79 (12.5)44 (6.9)294 (46.4)66 (10.4) 61 (17.1)21 (5.9)10 (2.8)234 (65.7)30 (8.4) <.001 Admission duration 16.6 (SD 27.7)14.2 (SD 27.8).213 Discharge destination Home Other health care facility Nursing/group home Not applicable Not available 05 (16.6)311 (49.1)8 (1.3)141 (22.2)69 (10.9) 9 (19.4)181 (50.8)2 (0.6)74 (20.8)30 (8.4).506Bold value: meets threshold for statistical significance P-value <0.05. Patient characteristics at time of aSAH. Bold value: meets threshold for statistical significance P-value <0.05. Results Patient characteristics A total of 990 patients with aSAH occurring after baseline assessment were included in the analysis. This cohort included 634 (64.0%) females with a mean age at time of aSAH of 66.0 years (SD 8.4) and 356 (36.0%) males with a mean age of 65.1 years (SD 8.6). Tables 1 and 2 provide the summary baseline characteristics, stratified by sex. At baseline assessment, there were statistically significant differences between both sexes in smoking status, alcohol status, diabetes status, use of anti-hypertensives and cholesterol-lowering medication, BMI and average household income. Of all included participants, 96 (9.7%) died out of hospital prior to admission, of which 66 females (10.4%) and 30 males (8.4%). Median follow-up time from UK Biobank recruitment to death or censoring was 130 months (censoring date 23 March 2021). Primary outcome At 90 days post-aSAH, the overall CFR was 31.5%; 214 of 634 females (33.8%) and 98 of 356 males (27.5%) had died (OR 1.34; 95% CI, 1.01–1.78). Kaplan–Meier survival analysis until 90 days after aSAH stratified by sex (log-rank P = .046) is presented in Figure 1. In univariate Cox regression analysis, the crude HR for risk of death at 90 days for females was 1.27 (95% CI, 1.00–1.61). Survival analyses for primary and secondary outcomes are presented in Table 3. In multivariable Cox regression analysis, adjusting for age and covariates that varied significantly by sex at baseline and at time of aSAH, HR for death at 90 days for females was 1.15 (95% CI, 0.90–1.49). Full results of the pooled multivariable Cox regression model for CFR at 90 days are presented in Supplementary Material 2. Kaplan Meier survival analysis at 90 days after aSAH stratified by sex. The event is defined as case fatality. The y-axis represents survival probability, and the x-axis represents time in days. Survival curves are stratified by sex, with males shown in blue and females in red. Group differences were assessed using the log-rank test. Table 3Case fatality rates and survival analysis per sex—primary and secondary outcomes.Total (n = 990)Total, n (%)Female, n (%)Male, n (%)HR (95% CI)Log-rank P-value634 (64.0)356 (36.0)Interval SAH—death (days)Mean (SD)301.3 (702.8)416.1 (841.4).213 Primary outcome CFR at 90 days312 (31.5)214 (33.8)98 (27.5)1.27 (1.00–1.61).046 Secondary outcome CFR at 30 days288 (29.1)196 (30.9)92 (25.8)1.10 (0.86–1.41).409CFR at 1 year331 (33.4)225 (35.5)106 (29.8)1.23 (0.98–1.55).066Overall CFR395 (39.9)264 (41.6)131 (36.8)1.16 (0.94–1.43).123 Case fatality rates and survival analysis per sex—primary and secondary outcomes. Sex-specific multivariable Cox proportional hazard analysis demonstrated that 90-day CFR in females was independently associated with age (HR 1.04; 95% CI, 1.02–1.06), the use of anti-hypertensives (HR 1.76; 95% CI, 1.23–2.51) and current smoking status (HR 1.87; 95% CI, 1.31–2.67). In males, both age (HR 1.04; 95% CI, 1.01–1.07) and the use of anti-hypertensives (HR 1.98; 95% CI, 1.23–3.17) were independently associated with 90-day CFR. Other co-morbidities or socio-economic status (average household income) did not affect sex-specific CFRs. (Figure 2). Sex-specific multivariable adjusted cox proportional analysis for 90-day CFR. Hazard ratios (HRs) with 95% confidence intervals (CIs) are shown for each covariate, stratified by sex, with females displayed in the left panel and males in the right panel. Points represent HR estimates and horizontal lines indicate their 95% CI. The vertical reference line corresponds to HR = 1.0. The event is defined as case fatality at 90 days. Secondary outcomes Also, at 30 days and 1 year after aSAH females consistently showed a higher CFR, although these differences did not reach statistical significance (Table 3). In females, survival analysis and multivariable adjusted Cox regression analysis demonstrated that CFR within 1 year and overall CFR remained associated with age (1-year: HR 1.04 [95% CI, 1.02–1.06] and overall CFR: HR 1.05 [1.03–1.07]), use of anti-hypertensive drugs (1-year: HR 1.65 [1.16–2.33] and overall CFR: HR 1.48 [1.07–2.05]) and current smoking status (1-year: HR 1.83 [1.29–2.59] and overall: HR 1.60 [1.17–2.22]). In males, survival analysis and multivariable adjusted Cox regression analysis demonstrated that CFR both within 1 year and overall CFR remained associated with age (1-year: HR 1.04 [95% CI, 1.01–1.07] and overall CFR: HR 1.05 [1.02–1.08]) and use of anti-hypertensive drugs (1-year: HR 2.11 [1.34–3.32] and overall CFR: HR 1.96 [1.30–2.95]). Discussion In the UK Biobank, a statistically significant unadjusted difference in 90-day CFR between both sexes was observed, with a higher case fatality and a lower cumulative probability of survival in females. At the other time points, females also had a higher CFR than males, but not to a statistically significant extent. The sex difference in 90-day CFR attenuated to non-significance after adjustment for age and modifiable baseline risk factors such as hypertension and smoking, suggesting these partially explain the observed disparity. In sex-specific analyses, age and anti-hypertensive use were independently associated with 90-day fatality in both sexes and current smoking was independently associated with 90-day CFR in females but not in males. These stratified analyses were descriptive, no formal interaction term was tested. Additionally, point estimates and CI overlapped across covariates, therefore these findings should not be interpreted as confirmed sex-specific effects. A smaller statistical power in males may also explain this difference, since two-thirds of the aSAH patients were females. Another uncertainty is that the smoking status was assessed at study entry, and not at the time of aSAH. If the proportions of participants who quit smoking between study entry and the occurrence of aSAH have differed between males and females, this may also have influenced the results. The overall 90-day CFR in our study was 31.5%, which is consistent with previous studies.3,6,7 However, prior studies have not demonstrated consistent sex differences in CFR following aSAH. In a recent systematic review and meta-analysis including 33 study cohorts, only 3 studies reported statistically significant CFR differences between females and males. In one of these 3 studies, females had a higher CFR, whereas in the other 2, females had a lower CFR.3 The inconsistencies in previously reported sex differences can be attributed to heterogeneity in study design or patient populations and multifactorial nature of outcomes in aSAH research as well as small sample sizes, inadequate adjustment for risk factors and heterogeneity in diagnostic accuracy and case identification.3,8 Although age, smoking and hypertension are known to differ between sexes and are known to be associated with case fatality after SAH,9,10 most of the previous studies did not adjust for these factors, because the studies had insufficient sample sizes to perform sound adjusted analyses. Most previous studies were found to have poor or unclear diagnostic accuracy and almost 40% of previous studies did not include sudden SAH deaths out of hospital, which could result in an underestimation of overall CFR after aSAH.3 Our study addresses all these methodological limitations. Our sample size of 990 SAH patients aligns with the previously proposed minimum of 976 cases needed to assess sex differences in CFR after aSAH with adequate power.3 Second, we adjusted appropriately for age and covariates that differed significantly by sex at baseline assessment and at time of aSAH. Third, the diagnostic accuracy of using ICD coding for aSAH within the UK Biobank has been confirmed.11 Fourth, through linkage to National death registries as well as hospitalisation records, our prospective population-based cohort study also captured non-hospitalised sudden-deaths due to SAH. Survival analyses demonstrated early divergence between sexes, indicating that sex-specific differences in CFR emerge shortly after aSAH, with females exhibiting worse short-term survival. Although no statistically significant difference in CFR was observed at 30 days, males who eventually died tended to survive longer after haemorrhage than females. This pattern may reflect a higher incidence of early complications, including cerebral vasospasm and delayed cerebral ischaemia, in female patients.12–14 Beyond the early phase, survival probabilities remained lower in females, but no statistically significant sex differences in CFR were observed at 1 year or thereafter. Our study fulfils all criteria for a high-quality study on sex-specific CFR differences in aSAH that were recently advocated.3 Our study examined sex-specific differences in CFR after aSAH as a primary research question, had a sufficient sample size, adequate confounder control, accurate SAH identification and inclusion of both hospitalised and non-hospitalised sudden deaths. Apart from these strong points, also some limitations need to be acknowledged. The identification of aSAH cases relied on ICD coding, which has been validated within the UK Biobank but still has inherent limitations. The inclusion of non-specific codes (I60.8, I60.9, ICD-9 430) may capture non-aneurysmal subarachnoid haemorrhages. However, within the UK Biobank these codes represent a substantially higher proportion of cases than would be expected for non-aneurysmal SAH in the general population, suggesting that true aSAH cases are recorded under these codes in this dataset.15–17 A sensitivity analysis excluding the unspecified SAH group is presented in the Supplementary material and demonstrated a consistent direction of effect, though statistical significance was not reached, likely reflecting reduced power given the smaller residual sample size. Second, as with any observational study, the potential influence of unmeasured variables cannot be fully excluded. Treatment-related data, procedural complications or in-hospital management were not captured in the UK Biobank. These may offer important explanatory insights into case fatality and could further influence sex-specific differences in CFR. Additionally, baseline lifestyle factors were assessed at study entry, potentially years before aSAH onset. Risk factor modification during this interval could lead to misclassification of exposure status, the direction and magnitude of which cannot be determined from the available data. Finally, the UK Biobank cohort may not be fully representative of the general population, as participants are generally healthier and less socioeconomically deprived.18 This could potentially limit the generalizability of our findings to broader SAH populations in different regions. Conclusion Females had a higher unadjusted 90-day CFR after aSAH than males. This difference attenuated to non-significance after adjustment for age and modifiable baseline risk factors such as hypertension and smoking, suggesting these partially explain the observed disparity. Future studies should investigate treatment- and complication-related contributors to sex disparities in aSAH outcomes. Supplementary Material